Mental healthcare is facing a growing imbalance between demand and available specialists. AI-native telepsychiatry provider Blossom Health is stepping into this gap with a fresh approach, with $20 million in combined seed and series A funding. The round was led by Headline, with co-founder and managing partner Mathias Schilling joining the company’s board.
Returning investors Village Global and TA Ventures participated alongside new backers, including Operator Partners and Correlation Ventures. A long list of angel investors also joined, featuring founders behind companies such as General Catalyst, Flatiron Health, Sword Health, and Zip.
The newly raised capital will be used to extend Blossom’s footprint across more US states and strengthen partnerships with both national and regional health insurance providers. The company also plans to onboard more clinicians and continue investing in research to advance its technology.
The backbone of modern psychiatry
Blossom positions itself as a single operating layer for psychiatry, one that connects every part of the care journey. Rather than offering isolated tools, it brings together clinicians, patients, insurers, pharmacists, and referral networks into one coordinated system.
At its core, the platform acts as the foundation on which multiple digital assistants and clinical tools operate together. These systems work alongside psychiatrists, streamlining interactions and ensuring information flows seamlessly across stakeholders.
This unified structure addresses one of healthcare’s longstanding challenges: fragmentation. By aligning every participant within a single environment, Blossom enables more consistent and efficient care delivery at scale.
Supports clinical decisions with precision
A key part of Blossom’s offering lies in its clinical copilots, which assist psychiatrists in complex decision-making. These tools help clinicians evaluate symptoms, refine diagnoses, and design treatment plans tailored to individual patients.
Medication selection, often a delicate and iterative process in psychiatry, is also supported. By surfacing relevant insights at the right moment, the platform helps clinicians make more informed choices.
With thousands of patients treated through the platform, Blossom has shown it can stabilise mental health conditions and even reverse progression toward more severe stages requiring intensive care. This ability to intervene early and effectively is critical in improving long-term outcomes.
Removes the burden behind the scenes
Founded by John Zhao in 2024 in New York, Blossom tackles one of the biggest pain points in healthcare: administration. Running a psychiatric practice often involves a heavy load of non-clinical tasks, from billing to scheduling and documentation.
Blossom replaces much of this complexity with a network of digital support roles. These include billing assistants, schedulers, receptionists, care coordinators, and medical scribes. By handling routine workflows, the system allows psychiatrists to focus on what matters most, which is patient care.
This shift not only improves efficiency but also reduces burnout among clinicians. With fewer administrative distractions, providers can deliver higher-quality care while managing larger patient volumes.
Most patients are able to secure appointments within 48 hours, with many seen on the same day. In a field where delays can worsen conditions, this level of responsiveness sets a new benchmark.
Blossom already works with all major commercial insurers, including Optum UnitedHealthcare, Aetna, Cigna Evernorth, and Blue Cross Blue Shield. This broad coverage keeps patient costs low, with average copays around $22, making psychiatric care more accessible.
“Mental Health is the singular most important public health crisis in America,” said John Zhao, Founder and CEO of Blossom Health. “Tens of millions of Americans are suffering because of an acute shortage in psychiatric care. By productising AI to supercharge psychiatrists, Blossom is finally making psychiatry affordable and attainable for every American in need.”
“Blossom is addressing one of the most urgent and consequential challenges in modern healthcare with extraordinary focus and technological depth,” said Mathias Schilling, Co-Founder and Managing Partner of Headline. “Their AI operating system is not just improving access to psychiatric care-it’s fundamentally redefining how clinicians practice and how patients heal. We believe Blossom has the potential to become the technological backbone of modern mental health, bridging the gap between overwhelming demand and limited clinical supply.”
